<DOC>
	<DOC>NCT01344655</DOC>
	<brief_summary>This is a crossover Study to investigate the effect of Formoterol versus Salmeterol on small airways physiological parameters in COPD patients.</brief_summary>
	<brief_title>Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients</brief_title>
	<detailed_description>A Single-centre, Double-blind, Double-dummy, Randomised, Crossover Study to investigate the effect of Formoterol HFA-pMDI versus Salmeterol HFA-pMDI on small airways physiological parameters in COPD patients.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Patients with a clinical diagnosis of COPD Post bronchodilator FEV1 between 30% and 80% predicted values at screening Postbronchodilator FEV1/FVC &lt; 0.7 Positive FEV1 reversibility test: FEV1 change greater than 200 mL and 12% History of another medical condition contraindicating participation in the study Clinical evidence of heart failure</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>